1-tert-butyl-5-(4-chloro-phenyl)-biguanide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-tert-butyl-5-(4-chloro-phenyl)-biguanide
• 英文别名: 1-tert-Butyl-5-(4-chlor-phenyl)-biguanid；1-[amino-(4-chloroanilino)methylidene]-2-tert-butylguanidine
• 化学式: C₁₂H₁₈ClN₅
• 分子量: 267.761
• InChiKey: FCCLQFHOIGGLLD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  88.8
• 氢给体数：
  3
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-(4-chloro-phenyl)-N-cyano-triazene-1-carboxamidine 在 盐酸 、 乙醇 、 1-乙氧基乙醇 、 copper(II) sulfate 作用下， 生成 1-tert-butyl-5-(4-chloro-phenyl)-biguanide
  参考文献：
  名称：

  149.合成抗疟药。第十部分。一些芳基-双胍（“-双胍”）衍生物

  摘要：

  DOI：

  10.1039/jr9460000729

文献信息

• BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR RENAL THERAPY
  申请人：Whiteford Jeffery A.

  公开号：US20100004218A1

  公开（公告）日：2010-01-07

  A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, one or more bridged polycyclic compounds may be administered to a subject to control fluid and/or waste levels.

  描述了一种药用活性剂、一种药用活性剂载体及其使用方法。在一些实施例中，系统可能包括一种组合物。该组合物可能包括一个或多个桥联多环化合物。至少一个桥联多环化合物可能包括至少两个环状基团，并且至少两种药用活性剂可能与桥联多环化合物相关联。在一些实施例中，一个或多个桥联多环化合物可以被用于控制主体的液体和/或废物水平。
• BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING CHOLESTEROL LEVELS
  申请人：Whiteford Jeffery A.

  公开号：US20100016270A1

  公开（公告）日：2010-01-21

  A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, one or more bridged polycyclic compounds may be administered to a subject to improve cardiac and/or cardiovascular health. In some embodiments, one or more bridged polycyclic compounds may be administered to a subject to control cholesterol levels.

  本文描述了一种药理活性剂、药理活性剂载体及其使用方法。在某些实施例中，该系统可能包括一种组合物。该组合物可能包括一个或多个桥接多环化合物。其中至少一个桥接多环化合物可能包括至少两个环状基团，并且至少有两种药理活性剂可能与桥接多环化合物相关联。在某些实施例中，可以向受试者施用一个或多个桥接多环化合物以改善心脏和/或心血管健康。在某些实施例中，可以向受试者施用一个或多个桥接多环化合物以控制胆固醇水平。
• Bridged polycyclic compound based compositions for topical applications for pets
  申请人：Whiteford Jeffery A.

  公开号：US20090069435A1

  公开（公告）日：2009-03-12

  A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, one or more bridged polycyclic compounds may be applied to an topical surface and/or an otic surface of an animal (e.g., canine, feline) such that an topical malady and/or otic malady may be inhibited and/or ameliorated.
• Bridged polycyclic compound based compositions for coating oral surfaces in pets
  申请人：Whiteford Jeffery A.

  公开号：US20090054528A1

  公开（公告）日：2009-02-26

  A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, one or more bridged polycyclic compounds may be applied to an oral surface of an animal (e.g., canine, feline) such that an oral malady may be inhibited and/or ameliorated.
• BRIDGED POLYCYCLIC COMPOUND BASED COMPOSITIONS FOR CONTROLLING BONE RESORPTION
  申请人：Whiteford Jeffery A.

  公开号：US20090074833A1

  公开（公告）日：2009-03-19

  A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, a composition may be administered to a subject to control bone resorption, inflammation, and/or pain.